WINSTON-SALEM, N.C., Jan. 5, 2012 /PRNewswire around COMTEX/ –
Tengion, Inc.
/quotes/zigman/116156/quotes/nls/tngn TNGN
-0.38%
, a personality in regenerative medicine, currently announced it has finished a relocation of a corporate domicile from East Norriton, Pennsylvania to a Company’s existent trickery in Winston-Salem, North Carolina. The relocation is partial of a Company’s formerly announced restructuring, that was designed to account a Company’s lead growth programs by pivotal milestones in 2012 while shortening expected money utilization. The Company will continue to say a Pennsylvania trickery while it explores options to significantly revoke a net let requirement for a facility.
“We are vehement to pierce a corporate domicile to Winston-Salem after carrying most of a investigate and growth operations located here given 2004,” pronounced John L. Miclot, President and Chief Executive Officer. “This relocation allows us to concentration a resources some-more good on advancing a Neo-Urinary Conduit(TM) and Neo-Kidney Augment(TM) programs. The participation of a well-educated, high-quality workforce was also a means in a preference to pierce a domicile to Winston-Salem.”
“We are gay to acquire Tengion to a North Carolina family of life sciences companies,” pronounced Norris Tolson, President and CEO of a North Carolina Biotechnology Center. “We are unequivocally gratified to hear that this personality in regenerative medicine is creation North Carolina a home.”
Tengion is stability to allege a ongoing Phase 1 clinical hearing of a Neo-Urinary Conduit, that is being evaluated in bladder cancer patients requiring a urinary diversion following bladder dismissal (cystectomy). This hearing is designed to consider a reserve and rough efficiency of a Neo-Urinary Conduit in adult to 10 patients, as good as to concede a clinical investigators to optimize a surgical procession and post-surgical caring by incorporating a outcomes celebrated in any studious into a surgical proceed for successive patients, as necessary. Three patients have been enrolled and ingrained to date during a University of Chicago and The Johns Hopkins Hospital. The Company anticipates implanting a fourth studious during a initial entertain of this year, and, presumption suitable reserve data, adult to 10 patients by a finish of 2012.
Tengion is also stability a preclinical growth of a Neo-Kidney Augment(TM) module toward a acquiescence of a Pre-IND filing to a U.S. Food and Drug Administration (FDA) during a initial half of this year.
About TengionTengion, a clinical-stage biotechnology company, has pioneered a Organ Regeneration Platform(TM) that enables a Company to emanate exclusive product possibilities that are dictated to strap a unique regenerative pathways of a physique to furnish a operation of native-like viscera and tissues. Tengion’s product possibilities find to discharge a need to implement other tissues of a physique for a purpose to that they are feeble suited, gain donor viscera or discharge anti-rejection medications. An initial clinical hearing is ongoing for a Company’s lead product candidate, a Neo-Urinary Conduit(TM), an autologous make that is dictated to catalyze metamorphosis of native-like bladder hankie for bladder cancer patients requiring a urinary diversion following bladder removal. The Company’s lead preclinical claimant is a Neo-Kidney Augment(TM), that is designed to check or forestall a need for dialysis or transplantation in patients during risk for kidney failure. Tengion has also practical a record in dual Phase II clinical trials for Tengion’s Neo-Bladder Augment(TM) for a diagnosis of neurogenic bladder. Tengion has worldwide rights to a product candidates.
Forward-Looking Statements Certain statements set onward above might consecrate forward-looking statements within a definition of a Private Securities Litigation Reform Act of 1995, including, though not singular to a Company’s: (i) skeleton to rise and commercialize a product candidates, including a Neo-Kidney Augment and a Neo-Urinary Conduit; and (ii) expectations per ongoing and designed preclinical studies and clinical trials. Although Tengion believes that these statements are formed on reasonable assumptions within a end of a believe of a business and operations, there are a series of factors that might means tangible formula to differ from these statements. For instance there can be no declaration that: (i) a Company will be means to successfully enroll patients in a clinical trials, including a Phase we clinical hearing for a Neo-Urinary Conduit; (ii) patients enrolled in a Company’s clinical trials will not knowledge inauspicious events associated to a Company’s product candidates, that could check clinical trials or means a Company to cancel a growth of a product candidate; (iii) a formula of a clinical hearing for a Neo-Urinary Conduit will support serve growth of that product candidate; (iv) information from a Company’s ongoing preclinical studies will continue to be understanding of advancing a preclinical product candidates; and (v) a Company will be means to swell a product possibilities that are undergoing preclinical testing, including a Neo-Kidney Augment, into clinical trials; (vi) a Company will be means enter into vital partnerships on auspicious terms, if during all, or obtain a collateral it needs to rise a product possibilities and continue a operations and (vii) a Company will be means to revoke a net let requirement for a Pennsylvania trickery before to a death of a existent lease. For additional factors that could means tangible formula to differ from expectations, anxiety is done to a reports filed by a Company with a Securities and Exchange Commission underneath a Securities Exchange Act of 1934, as amended. The brazen looking statements in this recover are done usually as of a date hereof and a Company disclaims any goal or shortcoming for updating predictions or expectations in this release.
SOURCE Tengion, Inc.
Copyright (C) 2012 PR Newswire. All rights reserved
/quotes/zigman/116156/quotes/nls/tngn
Add TNGN to portfolio
